Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026
Amylyx Pharmaceuticals announced it will host an investor event at the upcoming ObesityWeek® 2026 conference, featuring experts in post-bariatric hypoglycemia (PBH).
Stocks · News reference
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
Amylyx Pharmaceuticals reported its third-quarter 2026 financial results, highlighting positive topline data from the Phase 3 LUCIDITY trial of avexitide and a strengthened balance sheet.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Amylyx Pharmaceuticals announced its participation in upcoming investor conferences scheduled for November 2026.
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results
Amylyx Pharmaceuticals has scheduled the release of its financial results for the third quarter of 2026 for November 5, 2026.
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
Amylyx Pharma Q2 2026 Earnings Call Transcript
Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our